Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, today announced
that its President and CEO Richard T. Schumacher was recently featured on The
Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher
discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one
revenue-generating division. We now have three, each based on our proprietary
PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher
said in the podcast. “Our PCT platform supports our primary business, which is
selling pressure-based instruments and consumables to research laboratories
worldwide. Our customers include some of the world’s foremost protein chemists,
working in many of the finest academic, government, biotech, and pharma
laboratories around the globe. These scientists use PCT systems for a number of
different protein, RNA, and DNA applications as they search to find new
biomarkers of disease, diagnostic tools, druggable targets, and therapeutics.”
To listen to the podcast, visit http://ibn.fm/OGK48
To view the full press release, visit http://ibn.fm/5YWIR
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into
the biologics contract research services sector, and (2) the use of its
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality,
homogenized, extended shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions and
agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
